mannose/inflammation

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to novel phosphotetrahydropyran compounds, primarily derivatives of mannose-6-phosphate, and their use in treating diseases or disorders that are mediated at least in part by T lymphocyte emigration from

The present invention relates to galactosylated pro-drugs of non-steroidal anti-inflammatories with free acid function and the process of synthesis thereof, which enables minimization of the gastrointestinal toxicity of the starting anti-inflammatory by means of esterification of its carboxylic

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to the fields of inflammation and carbohydrate and glycoprotein chemistry. More specifically, the present invention relates to novel disaccharide inhibitors of inflammation. 2. Description of the Related

TECHNICAL FIELD The instant invention relates to a method for the differential diagnosis of inflammatory bowel disease. In more detail, the instant invention relates to a method for the differential diagnosis between ulcerative colitis and Crohn's disease in a patient with inflammatory bowel

This application is filed under 35 U.S.C. .sctn.371 from International Patent Application No. PCT/JP94/00352, filed Mar. 4, 1994. FIELD OF THE INVENTION The present invention relates to the method for preparing Lewis-related compounds, especially Lewis x (Le.sup.x) and Lewis a (Le.sup.a) as well as

RELATED APPLICATIONS This application is the National Phase of International Application No. PCT/EP2016/068813, filed Aug. 5, 2016 which designated the U.S. and that International Application was published under PCT Article 21(2) in English, and claims priority to European Application Serial No.

The invention relates to peptidic or polypeptidic antagonists for the prevention or treatment of inflammatory bowel disease, and more particularly of Crohn's disease. It also relates to a method for diagnosing this disease. Inflammatory bowel disease (IBD) mainly consists of two disorders,

FIELD OF THE INVENTION This invention relates in general to treatment of inflammatory conditions and specifically to the use of amino acid molecules for the treatment of these conditions. LIST OF PRIOR ART The following is a list of prior art considered to be relevant to the subject matter of the

PRIORITY CLAIM This patent application claims priority to Indian Patent Application No. 939/DEP/2014, filed 1 Apr. 2014, the disclosure of which is incorporated herein by reference in its entirety. FIELD OF THE INVENTION The present invention relates to polymeric biosurfactants isolated from two

CROSS REFERENCE TO RELATED APPLICATIONS This application is the U.S. National Phase Application of PCT/HR2014/000022, filed Jun. 11, 2014, which claims priority to Croatian Patent Application No. P20130568A, filed Jun. 20, 2013, the contents of such applications being incorporated by reference

FIELD OF THE INVENTION The present invention relates to novel glycoforms of the soluble complement receptor type 1 (sCR1), and their uses in the diagnosis and therapy of disorders involving complement activity and various inflammatory and immune disorders. The invention also provides methods of

TECHNICAL FIELD The invention relates to compounds useful in the treatment of inflammation, allergic reactions, autoimmune diseases, cancer, and similar other conditions that are cell adhesion-dependent. More specifically, the invention concerns compounds, containing GalNAc lewis.sup.x as a mucin

FIELD OF THE INVENTION The present invention relates to novel glycoforms of the soluble complement receptor type 1 (sCR1), and their uses in the diagnosis and therapy of disorders involving complement activity and various inflammatory and immune disorders. The invention also provides methods of

BACKGROUND OF THE INVENTION Transforming Growth Factor .beta. (TGF-.beta.) is a potent growth regulatory protein and a key molecule implicated in various fibrotic (scarring) disorders. Most of the cells secrete TGF-.beta.1 in a predominantly inactive high molecular weight form, latent TGF-.beta.